PTC124 is an Orally Bioavailable Compound That Promotes Suppression of the Human CFTR-G542X Nonsense Allele in a CF Mouse Model

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2008 Feb 15

PMID 18272502

Citations 127

Authors

Ming Du

Xiaoli Liu

Ellen M Welch

Samit Hirawat

Stuart W Peltz

David M Bedwell

Affiliations

Soon will be listed here.

Abstract

Nonsense mutations inactivate gene function and are the underlying cause of a large percentage of the individual cases of many genetic disorders. PTC124 is an orally bioavailable compound that promotes readthrough of premature translation termination codons, suggesting that it may have the potential to treat genetic diseases caused by nonsense mutations. Using a mouse model for cystic fibrosis (CF), we show that s.c. injection or oral administration of PTC124 to Cftr-/- mice expressing a human CFTR-G542X transgene suppressed the G542X nonsense mutation and restored a significant amount of human (h)CFTR protein and function. Translational readthrough of the premature stop codon was demonstrated in this mouse model in two ways. First, immunofluorescence staining showed that PTC124 treatment resulted in the appearance of hCFTR protein at the apical surface of intestinal glands in Cftr-/- hCFTR-G542X mice. In addition, functional assays demonstrated that PTC124 treatment restored 24-29% of the average cAMP-stimulated transepithelial chloride currents observed in wild-type mice. These results indicate that PTC124 can effectively suppress the hCFTR-G542X nonsense mutation in vivo. In light of its oral bioavailability, safety toxicology profile in animal studies, and efficacy with other nonsense alleles, PTC124 has the potential to be an important therapeutic agent for the treatment of inherited diseases caused by nonsense mutations.

Citing Articles

Promoting readthrough of nonsense mutations in CF mouse model: Biodistribution and efficacy of NV848 in rescuing CFTR protein expression.

Fiduccia I, Corrao F, Zizzo M, Perriera R, Genovese F, Vitale E Mol Ther. 2024; 32(12):4514-4523.

PMID: 39473179 PMC: 11638873. DOI: 10.1016/j.ymthe.2024.10.028.

Suppressor tRNA in gene therapy.

Ruan J, Yu X, Xu H, Cui W, Zhang K, Liu C Sci China Life Sci. 2024; 67(10):2120-2131.

PMID: 38926247 DOI: 10.1007/s11427-024-2613-y.

Therapeutic targeting of nonsense mutations in cancer.

Strandgren C, Wiman K Ups J Med Sci. 2024; 129.

PMID: 38863730 PMC: 11165251. DOI: 10.48101/ujms.v129.10719.

Readthrough Activators and Nonsense-Mediated mRNA Decay Inhibitor Molecules: Real Potential in Many Genetic Diseases Harboring Premature Termination Codons.

Benslimane N, Loret C, Chazelas P, Favreau F, Faye P, Lejeune F Pharmaceuticals (Basel). 2024; 17(3).

PMID: 38543100 PMC: 10975577. DOI: 10.3390/ph17030314.

Nonsense mutation suppression is enhanced by targeting different stages of the protein synthesis process.

Wittenstein A, Caspi M, Rippin I, Elroy-Stein O, Eldar-Finkelman H, Thoms S PLoS Biol. 2023; 21(11):e3002355.

PMID: 37943958 PMC: 10684085. DOI: 10.1371/journal.pbio.3002355.

References

Howard M, Frizzell R, Bedwell D . Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat Med. 1996; 2(4):467-9. DOI: 10.1038/nm0496-467. View

Bedwell D, Kaenjak A, Benos D, Bebok Z, Bubien J, Hong J . Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line. Nat Med. 1997; 3(11):1280-4. DOI: 10.1038/nm1197-1280. View

Manuvakhova M, Keeling K, Bedwell D . Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system. RNA. 2000; 6(7):1044-55. PMC: 1369979. DOI: 10.1017/s1355838200000716. View

Wilschanski M, Yahav Y, Yaacov Y, Blau H, Bentur L, Rivlin J . Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med. 2003; 349(15):1433-41. DOI: 10.1056/NEJMoa022170. View

Culbertson M . RNA surveillance. Unforeseen consequences for gene expression, inherited genetic disorders and cancer. Trends Genet. 1999; 15(2):74-80. DOI: 10.1016/s0168-9525(98)01658-8. View

Rowntree R, Harris A . The phenotypic consequences of CFTR mutations. Ann Hum Genet. 2003; 67(Pt 5):471-85. DOI: 10.1046/j.1469-1809.2003.00028.x. View

Welch E, Barton E, Zhuo J, Tomizawa Y, Friesen W, Trifillis P . PTC124 targets genetic disorders caused by nonsense mutations. Nature. 2007; 447(7140):87-91. DOI: 10.1038/nature05756. View

Zsembery A, Jessner W, Sitter G, Spirli C, Strazzabosco M, Graf J . Correction of CFTR malfunction and stimulation of Ca-activated Cl channels restore HCO3- secretion in cystic fibrosis bile ductular cells. Hepatology. 2002; 35(1):95-104. DOI: 10.1053/jhep.2002.30423. View

Keeling K, Bedwell D . Clinically relevant aminoglycosides can suppress disease-associated premature stop mutations in the IDUA and P53 cDNAs in a mammalian translation system. J Mol Med (Berl). 2002; 80(6):367-76. DOI: 10.1007/s00109-001-0317-z. View

10.

. Population variation of common cystic fibrosis mutations. The Cystic Fibrosis Genetic Analysis Consortium. Hum Mutat. 1994; 4(3):167-77. DOI: 10.1002/humu.1380040302. View

11.

Hirawat S, Welch E, Elfring G, Northcutt V, Paushkin S, Hwang S . Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers. J Clin Pharmacol. 2007; 47(4):430-44. DOI: 10.1177/0091270006297140. View

12.

Koerner T, Hill J, Myers A, Tzagoloff A . High-expression vectors with multiple cloning sites for construction of trpE fusion genes: pATH vectors. Methods Enzymol. 1991; 194:477-90. DOI: 10.1016/0076-6879(91)94036-c. View

13.

Riordan J, Rommens J, Kerem B, Alon N, Rozmahel R, Grzelczak Z . Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989; 245(4922):1066-73. DOI: 10.1126/science.2475911. View

14.

Clancy J, Bebok Z, Ruiz F, King C, Jones J, Walker L . Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am J Respir Crit Care Med. 2001; 163(7):1683-92. DOI: 10.1164/ajrccm.163.7.2004001. View

15.

Du M, Jones J, Lanier J, Keeling K, Lindsey J, Tousson A . Aminoglycoside suppression of a premature stop mutation in a Cftr-/- mouse carrying a human CFTR-G542X transgene. J Mol Med (Berl). 2002; 80(9):595-604. DOI: 10.1007/s00109-002-0363-1. View

16.

Amrani N, Sachs M, Jacobson A . Early nonsense: mRNA decay solves a translational problem. Nat Rev Mol Cell Biol. 2006; 7(6):415-25. DOI: 10.1038/nrm1942. View

17.

Dawson D . Na and Cl transport across the isolated turtle colon: parallel pathways for transmural ion movement. J Membr Biol. 1977; 37(3-4):213-33. DOI: 10.1007/BF01940933. View

18.

Snouwaert J, Brigman K, Latour A, Malouf N, Boucher R, SMITHIES O . An animal model for cystic fibrosis made by gene targeting. Science. 1992; 257(5073):1083-8. DOI: 10.1126/science.257.5073.1083. View

19.

Wilschanski M, Famini C, Blau H, Rivlin J, Augarten A, Avital A . A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations. Am J Respir Crit Care Med. 2000; 161(3 Pt 1):860-5. DOI: 10.1164/ajrccm.161.3.9904116. View

20.

Bonetti B, Fu L, Moon J, Bedwell D . The efficiency of translation termination is determined by a synergistic interplay between upstream and downstream sequences in Saccharomyces cerevisiae. J Mol Biol. 1995; 251(3):334-45. DOI: 10.1006/jmbi.1995.0438. View